Sanofi (ENXTPA:SAN) entered into an agreement to acquire Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC for $1.6 billion on July 22, 2025. As part of the acquisition, Sanofi will acquire all shares in Vicebio Limited. The consideration consists of an upfront payment of $1.15 billion and an additional milestone payments of $450 million will be paid based on development and regulatory achievements. The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio?s ?Molecular Clamp? technology. The acquisition will not have a significant impact on Sanofi?s financial guidance for 2025. The transaction is subject to customary closing conditions, including receipt of regulatory approvals and is expected to close in Q4 2025.
Goodwin Procter (Uk) Llp acted as legal advisor to Vicebio Limited. Aisling Zarraga, Nicole Meyer, Tom McGrath, Jonathan Ford, Yohan Liyanage, Marly Didizian, Chris Smale, Cara Hegarty and Nick Marshall of Linklaters team has advised Sanofi on its acquisition of Vicebio, Russell Anderson, Simon Amies, Charity Williams, Emily Mason and Joe Sandys of Cooley advised Medicxi and other venture capital investors. Saad Khanani of Latham & Watkins LLP acted as a a advisor to Goldman Sachs Asset Management International.
Sanofi (ENXTPA:SAN) completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC on December 4, 2025.
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.
At the end of 2024, the group had 52 production sites worldwide.
In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation.
Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
